阿利西尤单抗联合瑞舒伐他汀、阿司匹林治疗动脉粥样硬化性缺血性脑卒中的临床效果  

Clinical Effect of Alirocumab Combined with Rosuvastatin and Aspirin in Treatment of Atherosclerotic Ischemic Stroke

作　　者：李华 Li Hua(Department of General Practice,The Second Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,Jiangsu Province,China)

机构地区：[1]徐州医科大学第二附属医院全科医学科,江苏徐州221000

出　　处：《中国社区医师》2025年第8期57-59,共3页Chinese Community Doctors

摘　　要：目的:分析阿利西尤单抗联合瑞舒伐他汀、阿司匹林治疗动脉粥样硬化性缺血性脑卒中的临床效果。方法:选取于2021年7月—2024年7月徐州医科大学第二附属医院就诊的动脉粥样硬化性缺血性脑卒中患者100例作为研究样本,采用随机数字表法分为两组,各50例。对照组采用瑞舒伐他汀联合阿司匹林治疗,单抗组在对照组基础上联合阿利西尤单抗治疗。对比两组疗效。结果:单抗组治疗总有效率高于对照组(P<0.05)。治疗后,两组甘油三酯、总胆固醇、低密度脂蛋白胆固醇水平降低,高密度脂蛋白胆固醇水平升高,且单抗组改善幅度大于对照组(P<0.05)。治疗后,两组颈动脉斑块厚度、颈动脉内膜中层厚度缩小,且单抗组小于对照组(P<0.05)。治疗后,两组美国国立卫生研究院卒中量表(NIHSS)评分降低,日常生活功能量表(ADL)评分升高,且单抗组NIHSS评分低于对照组,ADL评分高于对照组(P<0.05)。结论:阿利西尤单抗联合瑞舒伐他汀、阿司匹林治疗动脉粥样硬化性缺血性脑卒中的临床效果显著,可降低患者血脂水平,减轻神经缺损,改善患者生活自理能力。Objective:To analyze the clinical effect of alirocumab combined with rosuvastatin and aspirin in treatment of atherosclerotic ischemic stroke.Methods:A total of 100 patients with atherosclerotic ischemic stroke who were admitted to the Second Affiliated Hospital of Xuzhou Medical University from July 2021 to July 2024 were selected as study samples.They were divided into two groups using random number table method,with 50 cases in each group.The control group was treated with rosuvastatin combined with aspirin,and the alirocumab group was treated with alirocumab on the basis of control group.The efficacy of the two groups was compared.Results:The total effective rate of treatment in the alirocumab group was higher than that in the control group(P<0.05).After treatment,the levels of triglycerides,total cholesterol and low-density lipoprotein cholesterol decreased and the levels of high-density lipoprotein cholesterol increased in the two groups,and the improvement in the alirocumab group was greater than that in the control group(P<0.05).After treatment,the carotid plaque thickness and carotid intima-media thickness in the two groups reduced,and these parameters in the alirocumab group were smaller than those in the control group(P<0.05).After treatment,the National Institutes of Health Stroke Scale(NIHSS)scores decreased and the Activities of Daily Living(ADL)scores increased in the two groups,and the NIHSS score in the alirocumab group was lower than that in the control group,and the ADL score in the alirocumab group was higher than that in the control group(P<0.05).Conclusion:Alirocumab combined with rosuvastatin and aspirin has significant clinical effect in the treatment of atherosclerotic ischemic stroke,and can reduce blood lipid levels,alleviate neurological deficits,and improve patients'daily living ability.

关 键 词：动脉粥样硬化性缺血性脑卒中 阿司匹林 瑞舒伐他汀 阿利西尤单抗 

分 类 号：R541.4[医药卫生—心血管疾病]